PATIENT-REPORTED OUTCOMES AFTER 12 MONTHS OF MAINTENANCE THERAPY WITH CABOTEGRAVIR ▼ + RILPIVIRINE ▼ LONG-ACTING COMPARED WITH BICTEGRAVIR/EMTRICITABINE/ TENOFOVIR ALAFENAMIDE IN THE PHASE 3B SOLAR STUDY
This page intends to provide information presented at recent congresses relevant to your unsolicited enquiry. Regulations vary by country, and some information may be off label (not authorised) in your country. Please refer to local product information before prescribing. ViiV Healthcare do not advocate off -label use of their medicines.
NP-GBL-HVX-WCNT-230008 June 2023
Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221441.
If you are from outside the UK, you can report adverse events to GSK/ViiV by selecting your region and market, here.
